WebJun 14, 2011 · Major Finding: Among patients with metastatic triple-negative breast cancers, single-agent therapy with cisplatin or carboplatin produced an overall response rate of 30.2%.Data Source: Multicenter prospective phase II trial by the Translational Breast Cancer Research Consortium.Disclosures: The stud WebJul 12, 2024 · Triple-negative breast cancer (TNBC), lacks the expression of estrogen receptor (ER) and progesterone-receptor (PgR) and amplification of human epidermal growth factor receptor 2 (HER2)...
A triple combination gemcitabine + romidepsin + cisplatin to ...
WebApr 1, 2024 · Triple-negative tumor cells, a malignant subtype of breast cancer, lack a biologically targeted therapy. Given its DNA repair inhibiting properties, caffeine has been shown to enhance the effectiveness of specific tumor chemotherapies. In this work, we have investigated the effects of caffeine, cisplatin, and a combination of the two as potential … WebApr 12, 2024 · Triple-negative breast cancer (TNBC), accounting for 15–20% of all breast cancer (BC) cases, is one of the most aggressive BC subtypes 1.TNBC treatments … simple car accident release of liability
Central Nervous System Metastases from Triple-Negative Breast Cancer ...
WebJun 6, 2024 · Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of 21 days every 3 weeks for six cycles. TNBC subtype (basal v nonbasal) was determined by PAM50 in the residual disease. WebBetween 15–20% of all breast cancer cases are classified as triple negative breast cancers (TNBCs): Patients in this category have the highest rate of metastatic disease and the poorest prognosis [1,2].TNBC cells do not express well-established therapeutic targets including the estrogen and progesterone (ER and PR) receptors or human epidermal … WebJul 15, 2024 · Abstract Resistance to chemotherapy continues to be a critical issue in the clinical therapy of triple-negative breast cancer (TNBC). Epithelial-mesenchymal transition (EMT) is thought to contribute to chemoresistance in several … simple caractere shoes